Safety, Tolerability, and Immunogenicity of GTL001 Vaccine Adjuvanted With Imiquimod Cream in HPV 16- and/or HPV 18-Infected Women Aged 25 to 65 Years, With Normal Cytology, ASCUS, or LSIL

NCT02689726 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

13

Enrollment

INDUSTRY

Sponsor class

Stopped Lack of efficacy in European Phase 2 study

Conditions

HPV 16- and/or HPV 18-Infected Women With Normal Cytology, ASCUS, or LSIL

Interventions

DRUG: GTL001+
DRUG: Aldara

Sponsor

Genticel

Collaborators

[object Object]